Drug Trial Radar · NCT05879718
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Jul 7, 2023
Primary completion
Jun 5, 2025
Study completion Nov 18, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.
Conditions
- Lupus Erythematosus, Systemic
- Lupus Erythematosus, Cutaneous
Interventions
PlaceboDrug
Placebo (intravenous infusion)
PF-06823859Drug
PF-06823859 (intravenous infusion)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12Time frame: Baseline, Week 12
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama
University of Alabama at Birmingham - School of Medicine
Birmingham, Alabama
University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama
The University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic in Arizona - Scottsdale
Scottsdale, Arizona
Dermatology Research Associates
Los Angeles, California
Emory University
Atlanta, Georgia
The University of Kansas Hospital
Kansas City, Kansas
University of Kansas Medical Center
Kansas City, Kansas
Cleveland Clinic Foundation
Cleveland, Ohio
DermEffects
London, Ontario, Canada
Dermatology on Bloor - Research Toronto
Toronto, Ontario, Canada
Whitby Health Centre
Whitby, Ontario, Canada
Dermatological and Venereological Hospital Andreas Syggros
Athens, Greece
University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"
Chaïdári, Attikí, Greece
Ionos Dragoumi 5 Kaisariani
Kaisarianí, Attikí, Greece
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.